ALG-055009, Publications Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
ALG-000184, Publications Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B
Other, Publications Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model
Other, Publications The HBV siRNA, ALG-125755, demonstrates a favorable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model
Preclinical, Publications Discovery of oral PD-L1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B
Publication, Publications Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex
ALG-000184, Publications Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Asian and non-Asian Subjects with Chronic Hepatitis B (CHB)
ALG-000184, Publications Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Asian and non Asian Subjects with Chronic Hepatitis B (CHB)
Other, Publications Hepatitis B Surface Antigen (HBsAg) is Significantly Reduced by the HBV small interfering RNA (siRNA) ALG-125755 in HBV Infected Cells and the AAV HBV Mouse Model